News | Careers |Contact
Global

Great Bay Bio Won Best Innovation Award and TOP100 China's Innovative Medical Business and Supply Chain Service List

2023-05-08

[香港，2023年5月8日] 近日，由波士顿华人投资协会(Boston Chinese Investment Club, or BCIC)主办的2023国际生物医疗创业大赛和由VB100、动脉网、蛋壳研究院主办的第七届未来医疗100强大会成功举办，大湾生物相继斩获最佳创新奖与中国创新医疗商业及供应链服务榜TOP100。


BCIC2023国际生物医疗创业大赛•最佳创新奖（左一）与2023未来医疗100强•中国创新医疗商业及供应链服务榜TOP100（右一）



2023国际生物医疗创业大赛目的在于向公众和投资机构展现世界最具创新力的创赛团队，帮助中国生物医疗企业出海美国市场，决赛从全球各地的85+初创企业中选拔18个队伍。大湾生物作为生物组唯一一支亚洲区队伍，在决赛与美国几大知名药企进行激烈角逐，并最终斩获BCIC2023国际生物医疗创业大赛•最佳创新奖。


大湾生物CCO齐凯博士出席2023国际生物医疗创业大赛决赛线上路演

第七届未来医疗100强大会旨在遴选真正代表未来医疗的中国创新医疗者，发现我国未来医疗产业的核心力量，推动健康医疗产业的创新变革进程。评选标准包括企业的创新能力、技术创新水平、人力资源、知识资源、重要合作伙伴资源、市场表现等多个方面。大湾生物通过评审，成功跻身2023未来医疗100强•中国创新医疗商业及供应链服务榜TOP100。



大湾生物CEO兼联合创始人陈亮博士出席2023未来医疗100强大会圆桌会议


大湾生物CCO齐凯博士（右八）出席第七届未来医疗100强大会颁奖典礼


大湾生物跻身2023未来医疗100强•中国创新医疗商业及供应链服务榜TOP100榜单


Back
Recent News
Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

2026-05-20
Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

2026-03-27
Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

2026-03-26
Global Bioprocessing Made Simpler and More Efficient
Schedule a Meeting

Schedule a Meeting

I agree to the privacy policy.

Submit
COPYRIGHT 2026 © Great Bay Bio ALL RIGHTS RESERVD.